Development and in vitro evaluation of lipid nanoparticle-based dressings for topical treatment of chronic wounds

G. Gainza, W. S. Chu, R. H. Guy, J. L. Pedraz, R. M. Hernandez, B. Delgado-Charro, M. Igartua

Research output: Contribution to journalArticle

18 Citations (Scopus)
110 Downloads (Pure)

Abstract

This research addresses the development and in vitro evaluation of lipid nanoparticle (NP)-based dressings to optimize the delivery of human recombinant epidermal growth factor (rhEGF) for the topical treatment of chronic wounds. The systems investigated were rhEGF-loaded solid lipid nanoparticles (rhEGF-SLN) and rhEGF-loaded nanostructured lipid carriers (rhEGF-NLC) formulated in wound dressings comprising either semi-solid hydrogels or fibrin-based solid scaffolds. Following detailed characterisation of the NP, in vitro diffusion cell experiments (coupled with dermatopharmacokinetic measurements), together with confocal microscopic imaging, conducted on both intact skin samples, and those from which the barrier (the stratum corneum) had been removed, revealed that (a) the particles remained essentially superficially located for at least up to 48 h post-application, (b) rhEGF released on the surface of intact skin was unable to penetrate to the deeper, viable layers, and (c) sustained release of growth factor from the NP "drug reservoirs" into barrier-compromised skin was observed. There were no significant differences between the in vitro performance of rhEGF-SLN and rhEGF-NLC, irrespective of the formulation employed. It is concluded that, because of their potentially longer-term stability, the fibrin-based scaffolds may be the most suitable approach to formulate rhEGF-loaded lipid nanoparticles.

Original languageEnglish
Pages (from-to)404-411
Number of pages8
JournalInternational Journal of Pharmaceutics
Volume490
Issue number1-2
Early online date12 Jun 2015
DOIs
Publication statusPublished - 25 Jul 2015

Fingerprint

Bandages
Nanoparticles
Lipids
Wounds and Injuries
Fibrin
Skin
Hydrogels
Epidermal Growth Factor
Cornea
In Vitro Techniques
Intercellular Signaling Peptides and Proteins
Research
Pharmaceutical Preparations

Keywords

  • EGF (epidermal growth factor)
  • Lipid nanoparticles
  • Nanostructured lipid carriers
  • Skin
  • Solid lipid nanoparticles
  • Stratum corneum
  • Wound dressing

Cite this

Development and in vitro evaluation of lipid nanoparticle-based dressings for topical treatment of chronic wounds. / Gainza, G.; Chu, W. S.; Guy, R. H.; Pedraz, J. L.; Hernandez, R. M.; Delgado-Charro, B.; Igartua, M.

In: International Journal of Pharmaceutics, Vol. 490, No. 1-2, 25.07.2015, p. 404-411.

Research output: Contribution to journalArticle

@article{bba2810a9062442684d650fe590d9207,
title = "Development and in vitro evaluation of lipid nanoparticle-based dressings for topical treatment of chronic wounds",
abstract = "This research addresses the development and in vitro evaluation of lipid nanoparticle (NP)-based dressings to optimize the delivery of human recombinant epidermal growth factor (rhEGF) for the topical treatment of chronic wounds. The systems investigated were rhEGF-loaded solid lipid nanoparticles (rhEGF-SLN) and rhEGF-loaded nanostructured lipid carriers (rhEGF-NLC) formulated in wound dressings comprising either semi-solid hydrogels or fibrin-based solid scaffolds. Following detailed characterisation of the NP, in vitro diffusion cell experiments (coupled with dermatopharmacokinetic measurements), together with confocal microscopic imaging, conducted on both intact skin samples, and those from which the barrier (the stratum corneum) had been removed, revealed that (a) the particles remained essentially superficially located for at least up to 48 h post-application, (b) rhEGF released on the surface of intact skin was unable to penetrate to the deeper, viable layers, and (c) sustained release of growth factor from the NP {"}drug reservoirs{"} into barrier-compromised skin was observed. There were no significant differences between the in vitro performance of rhEGF-SLN and rhEGF-NLC, irrespective of the formulation employed. It is concluded that, because of their potentially longer-term stability, the fibrin-based scaffolds may be the most suitable approach to formulate rhEGF-loaded lipid nanoparticles.",
keywords = "EGF (epidermal growth factor), Lipid nanoparticles, Nanostructured lipid carriers, Skin, Solid lipid nanoparticles, Stratum corneum, Wound dressing",
author = "G. Gainza and Chu, {W. S.} and Guy, {R. H.} and Pedraz, {J. L.} and Hernandez, {R. M.} and B. Delgado-Charro and M. Igartua",
year = "2015",
month = "7",
day = "25",
doi = "10.1016/j.ijpharm.2015.05.075",
language = "English",
volume = "490",
pages = "404--411",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Development and in vitro evaluation of lipid nanoparticle-based dressings for topical treatment of chronic wounds

AU - Gainza, G.

AU - Chu, W. S.

AU - Guy, R. H.

AU - Pedraz, J. L.

AU - Hernandez, R. M.

AU - Delgado-Charro, B.

AU - Igartua, M.

PY - 2015/7/25

Y1 - 2015/7/25

N2 - This research addresses the development and in vitro evaluation of lipid nanoparticle (NP)-based dressings to optimize the delivery of human recombinant epidermal growth factor (rhEGF) for the topical treatment of chronic wounds. The systems investigated were rhEGF-loaded solid lipid nanoparticles (rhEGF-SLN) and rhEGF-loaded nanostructured lipid carriers (rhEGF-NLC) formulated in wound dressings comprising either semi-solid hydrogels or fibrin-based solid scaffolds. Following detailed characterisation of the NP, in vitro diffusion cell experiments (coupled with dermatopharmacokinetic measurements), together with confocal microscopic imaging, conducted on both intact skin samples, and those from which the barrier (the stratum corneum) had been removed, revealed that (a) the particles remained essentially superficially located for at least up to 48 h post-application, (b) rhEGF released on the surface of intact skin was unable to penetrate to the deeper, viable layers, and (c) sustained release of growth factor from the NP "drug reservoirs" into barrier-compromised skin was observed. There were no significant differences between the in vitro performance of rhEGF-SLN and rhEGF-NLC, irrespective of the formulation employed. It is concluded that, because of their potentially longer-term stability, the fibrin-based scaffolds may be the most suitable approach to formulate rhEGF-loaded lipid nanoparticles.

AB - This research addresses the development and in vitro evaluation of lipid nanoparticle (NP)-based dressings to optimize the delivery of human recombinant epidermal growth factor (rhEGF) for the topical treatment of chronic wounds. The systems investigated were rhEGF-loaded solid lipid nanoparticles (rhEGF-SLN) and rhEGF-loaded nanostructured lipid carriers (rhEGF-NLC) formulated in wound dressings comprising either semi-solid hydrogels or fibrin-based solid scaffolds. Following detailed characterisation of the NP, in vitro diffusion cell experiments (coupled with dermatopharmacokinetic measurements), together with confocal microscopic imaging, conducted on both intact skin samples, and those from which the barrier (the stratum corneum) had been removed, revealed that (a) the particles remained essentially superficially located for at least up to 48 h post-application, (b) rhEGF released on the surface of intact skin was unable to penetrate to the deeper, viable layers, and (c) sustained release of growth factor from the NP "drug reservoirs" into barrier-compromised skin was observed. There were no significant differences between the in vitro performance of rhEGF-SLN and rhEGF-NLC, irrespective of the formulation employed. It is concluded that, because of their potentially longer-term stability, the fibrin-based scaffolds may be the most suitable approach to formulate rhEGF-loaded lipid nanoparticles.

KW - EGF (epidermal growth factor)

KW - Lipid nanoparticles

KW - Nanostructured lipid carriers

KW - Skin

KW - Solid lipid nanoparticles

KW - Stratum corneum

KW - Wound dressing

UR - http://www.scopus.com/inward/record.url?scp=84930959076&partnerID=8YFLogxK

UR - http://dx.doi.org/10.1016/j.ijpharm.2015.05.075

U2 - 10.1016/j.ijpharm.2015.05.075

DO - 10.1016/j.ijpharm.2015.05.075

M3 - Article

VL - 490

SP - 404

EP - 411

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -